Astrazeneca Pharma India Ltd. (ASTRAZEN): Astrazeneca Pharma India 52 Week Low Streak: Second Straight Session of Weakness

Astrazeneca Pharma India Ltd. (ASTRAZEN) has now set a fresh 52-week low for its second straight session. The stock slipped to Rs 6,850, taking the cumulative move across the streak to -1.59%. The supplied data confirms the repeated-low pattern, but it does not establish any company-specific cause for the continued decline.

The stock closed at Rs 6,860 against the previous close of Rs 6,927.1, after opening at Rs 6,885 and trading between Rs 6,850 and Rs 6,892 during the session. Turnover stood at Rs 0.05 crore, while market capitalisation was Rs 17,317.75 crore. For readers, the key difference from a single-day breakdown is the repetition: this Astrazeneca Pharma India 52 Week Low Streak shows the one-year trough being reset again, not just touched once.

Astrazeneca Pharma India 52 Week Low Streak: Consecutive Low Analysis

Metric	Value
Current Price	Rs 6,860
Previous Close	Rs 6,927.1
Today's Move	Rs -67.1 (-0.97%)
Open	Rs 6,885
High	Rs 6,892
Low	Rs 6,850
Turnover	Rs 0.05 crore
Market Capitalisation	Rs 17,317.75 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,860. versus the previous close of Rs 6,927.1, a fall of 0.97%. The stock opened at Rs 6,885, reached Rs 6,892, touched Rs 6,850.

Astrazeneca Pharma India Share Price Today showed another weak session as the stock finished below the previous close and ended near the day’s lower band. The close of Rs 6,860 was Rs 67.1 lower than the previous close of Rs 6,927.1, a decline of 0.97% on the day. The opening price of Rs 6,885 was only slightly above the close, and the day’s high of Rs 6,892 stayed close to the opening level, while the low of Rs 6,850 matched the fresh 52-week low.

That price path places the close very near the bottom of the session range, which is relevant because the stock did not recover materially after the opening trade. Turnover of Rs 0.05 crore indicates the traded value available in the supplied data, and market capitalisation at Rs 17,317.75 crore keeps the company firmly in focus among listed healthcare names. In this Astrazeneca Pharma India Share Price Today update, the main point is not a one-off dip but the continuation of a fresh one-year low pattern across consecutive sessions. For ASTRAZEN, the repeated low becomes a more important signal than the day’s small absolute move alone.

What the Repeated 52-Week Lows Show

The Astrazeneca Pharma India 52 Week Low Streak now covers the second straight session, and that repeat matters more than the isolated daily change. A fresh one-year low on consecutive sessions tells readers that the stock has not only broken its earlier trough, but has also failed to move back above it in the next session. The current low of Rs 6,850 sits exactly at the latest yearly trough, with no higher floor provided in the data to suggest a stabilising band.

Across the full streak, the stock is down 1.59%, which is the cleanest way to read the cumulative move because that figure comes directly from the supplied data. The streak started on 2026-09-01 and extended again on 2026-09-02, making this a two-session pattern of repeated weakness. For investors scanning “Stocks Hitting 52 Week Lows” or “Stocks At One Year Low Today”, the useful distinction is that a second straight session can reflect persistence in the price pattern even when the company-specific reason is not established by the data. That is why the Astrazeneca Pharma India 52 Week Low Streak deserves separate attention from a normal single-day breakdown.

The current low is also Rs 77.1 below the previous event-day close of Rs 6,927.1, which helps frame how quickly the stock moved from one low checkpoint to the next. In plain terms, the price did not merely probe the earlier trough; it reset it again and closed close to the lower end of the session.

Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 17,317.75 crore
P/E Ratio	102.1x
P/B Ratio	19.15x
ROE	23.02%
ROCE	31.24%
EPS	Rs 67.85
Book Value Per Share	Rs 361.68
Dividend Yield	0.52%

Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 102.1x, P/B 19.15x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.

Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 17317.75 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 102.1x, P/B at 19.15x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.52%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.13x, median ROE of 11.78%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	102.1x
Benchmark Median P/E	31.13x
Benchmark Average P/E	47.8x
Benchmark P/E Range	3.68x to 653.31x
Company P/B Ratio	19.15x
Benchmark Median P/B	2.87x
Company ROE	23.02%
Benchmark Median ROE	11.78%
Company ROCE	31.24%
Benchmark Median ROCE	13.61%
Company Market Capitalisation	Rs 17,317.75 crore
Benchmark Median Market Cap	Rs 698.8 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 102.1x, which is above the benchmark median of 31.13x, a difference of +227.98%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.78%, a difference of +95.42%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.61%, a difference of +129.54%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Suven Pharmaceuticals Ltd.	COHANCE	17,456	165.58	4.57	4.02	6.12
Glenmark Life Sciences Ltd.	ALIVUS	17,722.67	29.39	5.09	18.41	24.61
Eris Lifesciences Ltd.	ERIS	17,987.42	27.94	4.45	13.81	13.59
Alembic Pharmaceuticals Ltd.	APLLTD	16,429.73	23.93	2.84	12.35	11.74
Shilpa Medicare Ltd.	SHILPAMED	18,581.25	58.49	6.47	9.82	11.43

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 102.1x compared with the displayed peer median of 29.39x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 12.35% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 11.74%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 17,317.75 crore. Among the 5 peers shown, 4 have a larger market capitalisation.

Why Investors Are Watching

• The Astrazeneca Pharma India 52 Week Low Streak has now extended to a second straight session, so the repeated low pattern itself is the main market event.
• The cumulative move across the streak is -1.59%, which provides a cleaner read than the day’s one-session decline alone.
• The latest low of Rs 6,850 is the fresh 52-week trough, and the stock closed close to that level.
• Valuation remains elevated at 102.1 times earnings and 19.15 times book, even as the price continues to weaken.
• ROE of 23.02% and ROCE of 31.24% show strong return metrics, so readers are watching how price action behaves relative to fundamentals.

About the Company

Astrazeneca Pharma India Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company’s listed equity trades on NSE and BSE as ASTRAZEN. Based on the supplied financial snapshot, the business shows a market capitalisation of Rs 17,317.75 crore, EPS of Rs 67.85, book value of Rs 361.68 and dividend yield of 0.52%. These numbers help place the stock in context, but they do not explain the repeated 52-week low pattern on their own.

For readers tracking Astrazeneca Pharma India Stock News, the important point is that the company combines a high valuation profile with strong return ratios and a fresh low streak in the share price. That contrast makes the current phase relevant for both fundamental and market-action monitoring.

Track Astrazeneca Pharma India on Univest

Use Univest to follow Astrazeneca Pharma India Share Price Today, company updates, and the next session in the Astrazeneca Pharma India 52 Week Low Streak. Readers can continue to monitor the latest price behaviour, sector comparison and market capitalisation on the stock’s dedicated page for a clearer view of how the repeated one-year low pattern develops.

Frequently Asked Questions

Why is Astrazeneca Pharma India still hitting 52-week lows?

Ans. The supplied data confirms that Astrazeneca Pharma India has made a fresh 52-week low for a second straight session, but it does not establish a company-specific cause for the repeated decline. The price pattern is confirmed; the reason is not.

How many sessions has Astrazeneca Pharma India been at a fresh 52-week low?

Ans. The stock has now set a fresh 52-week low for its second straight session. That makes this an Astrazeneca Pharma India 52 Week Low Streak rather than a one-day event.

What is the latest 52-week low for Astrazeneca Pharma India?

Ans. The latest fresh 52-week low is Rs 6,850. The stock also closed at Rs 6,860, leaving it very close to the newly set yearly trough. The stock moved -0.97% during the session.

How does the current low compare with the previous close?

Ans. The stock’s previous close was Rs 6,927.1, so the latest low of Rs 6,850 sits Rs 77.1 below that level. The day’s close was also lower than the previous close.

Is Astrazeneca Pharma India expensive or inexpensive on valuation?

Ans. Based on the supplied data and sector benchmark, the stock looks expensive on P/E and P/B. Its P/E of 102.1 and P/B of 19.15 are well above the industry median readings.

How do the fundamentals compare with the price trend?

Ans. The company’s ROE of 23.02% and ROCE of 31.24% are strong versus the benchmark set, but the share price continues to post fresh lows. That is a notable divergence for Astrazeneca Pharma India Stock Analysis.

What should investors monitor next?

Ans. Investors should track whether the stock stops resetting the one-year low in the next session, how the cumulative streak move evolves, and whether the current price behaviour starts to separate from the company’s return ratios and valuation profile.

Track Astrazeneca Pharma India Ltd. (ASTRAZEN) Share Price on Univest

Use Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.